A Phase 2 interventional study of TNX-102 SL and Placebo SL Tablet in Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19 and Long COVID, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 29 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 67th largest by enrollment of the 155 interventional ones that give a count, is one of 29 that started in 2022, is one of 47 in phase 2, and was the 44th registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Stephanie B. Seminara, MD · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 53 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 29 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is close to the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 52 across the 155 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 194 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
30 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 30 to your calendar (.ics) → With an account.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with Long COVID.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's enrollment of 63 is close to the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: TNX-102 SL
1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Daily Diary Pain NRS
Change from Baseline in the diary Numeric Rating Scale (NRS) weekly average of daily self-reported worst Long COVID pain intensity scores at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.
Time frame: Week 14
Daily Diary Sleep Quality NRS
Mean change from baseline in the weekly average of the daily diary numeric rating scale (NRS) assessment of sleep quality at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.
Time frame: Week 14
PROMIS Fatigue -Short Form 8a
Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for fatigue at the Week 14 endpoint. Subjects are asked to reflect on their fatigue symptoms in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
Time frame: Week 14
PROMIS Cognitive Function - Abilities-Short Form 8a
Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for cognitive function at the Week 14 endpoint. Subjects are asked to reflect on their cognitive function and abilities in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
Time frame: Week 14
| Milestone | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Started | 32 | 31 |
| Completed | 26 | 25 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 |
Change from Baseline in the diary Numeric Rating Scale (NRS) weekly average of daily self-reported worst Long COVID pain intensity scores at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.
| units on a scale | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Daily Diary Pain NRS | -2.2 ± 0.34 | -2.0 ± 0.35 |
Mean change from baseline in the weekly average of the daily diary numeric rating scale (NRS) assessment of sleep quality at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.
| units on a scale | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Daily Diary Sleep Quality NRS | -2.1 ± 0.38 | -1.6 ± 0.39 |
Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for fatigue at the Week 14 endpoint. Subjects are asked to reflect on their fatigue symptoms in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
| T-score | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| PROMIS Fatigue -Short Form 8a | -8.0 ± 1.65 | -3.2 ± 1.68 |
Change from Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) score for cognitive function at the Week 14 endpoint. Subjects are asked to reflect on their cognitive function and abilities in the past 7 days and respond to 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
| T-score | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| PROMIS Cognitive Function - Abilities-Short Form 8a | 5.4 ± 1.55 | 3.5 ± 1.55 |
Collected over Patients were monitored for AEs throughout the study. The total duration of the study, including screening and follow up, was as long as 25 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNX-102 SL Tablet, 5.6 mg | 0/32 (0%) | 0/32 (0%) | 12/32 (37.5%) |
| Placebo SL Tablet | 0/31 (0%) | 0/31 (0%) | 2/31 (6.5%) |
| Event | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet |
|---|---|---|
| Hypoaesthesia oralGastrointestinal disorders | 6/32 | 0/31 |
| Influenza like illnessGeneral disorders | 0/32 | 2/31 |
| GlossodyniaGastrointestinal disorders | 2/32 | 0/31 |
| Oral PainGastrointestinal disorders | 2/32 | 0/31 |
| Paraesthesia oralGastrointestinal disorders | 2/32 | 0/31 |
| Age, Continuous(years) | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| Mean | 48.6 ± 8.80 | 51.4 ± 10.01 | 50.0 ± 9.45 |
| Sex: Female, Male(Participants) | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| Female | 21 | 25 | 46 |
| Male | 11 | 6 | 17 |
| Race (NIH/OMB)(Participants) | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 21 | 24 | 45 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| BMI(kg/m^2) | TNX-102 SL Tablet, 5.6 mg | Placebo SL Tablet | Total |
|---|---|---|---|
| Mean | 29.78 ± 4.067 | 29.49 ± 4.439 | 29.64 ± 4.222 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Jul 2023, 10 months.
Results were first posted in Nov 2024, 1 year 4 months after primary completion.
Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Post-Acute COVID-19 Syndrome →